Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
NCT00400803
Completed
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2017
Locations: Hubert H. Humphrey Cancer Center, Minneapolis, Minnesota +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00023673
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2017
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +40 locations
Conditions: Lung Cancer
Register for Updates
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
NCT00755313
Completed
RATIONALE: Gathering information over time from laboratory tests, imaging scans, and assessment tests may help doctors learn more about the side effects of chemotherapy and plan the best treatment. PURPOSE: This clinical trial is studying the effects of chemotherapy on the brain in women with newly diagnosed early-stage breast cancer.
Gender:
FEMALE
Ages:
Between 35 years and 80 years
Trial Updated:
11/21/2017
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Register for Updates
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
NCT01525927
Terminated
This study looks at the use of three cycles of chemotherapy given prior to radiation therapy in patients with cancer of the oral cavity and evidence of prior exposure to Human Papilloma Virus (HPV). Patients with cancer of the oral cavity who have evidence of exposure to HPV have a better prognosis than those who do not have such evidence of exposure to HPV. The main hypothesis of this study is that using three cycles of chemotherapy prior to embarking on radiation therapy will allow the use of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2017
Locations: Long Island Jewish Medical Center, New Hyde Park, New York
Conditions: Oropharyngeal Neoplasms
Register for Updates
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
NCT00562185
Withdrawn
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving doxorubicin together with carboplatin may kill more tumor cells. PURPOSE: This phase I and phase II trial is studying the side effects and best dose of carboplatin when given together with doxorubicin to see how well it works in treating patients with recurrent ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
11/16/2017
Locations: Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas
Conditions: Ovarian Cancer
Register for Updates
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
NCT00461851
Completed
This is a Phase II, nonrandomized multicenter study designed to evaluate time to progression and response proportion of patients with advanced or metastatic transitional cell carcinoma of bladder receiving 6 cycles of gemcitabine, carboplatin and sorafenib and then maintenance sorafenib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2017
Locations: Yale University, Comprehensive Cancer Center, New Haven, Connecticut
Conditions: Bladder Cancer
Register for Updates
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
NCT00388076
Completed
Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and lapatinib (patients separated in each part). Toxicity monitoring will enable us to find the largest dose of pazopanib daily that can be safely given in combination with the chemotherapy agents TAXOL and PARAPLATIN, and with lapatinib, as well as what side effects are likely to manifest when these agents are given together an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2017
Locations: GSK Investigational Site, New Brunswick, New Jersey +2 locations
Conditions: Neoplasms, Breast
Register for Updates
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
NCT01192165
Completed
The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2017
Locations: GSK Investigational Site, Scottsdale, Arizona +19 locations
Conditions: Cancer
Register for Updates
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01015118
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/03/2017
Locations: 1199.15.10113 Boehringer Ingelheim Investigational Site, Tucson, Arizona +280 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Register for Updates
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
NCT00093756
Completed
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation therapy and to see how well they work in treating patients with stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +142 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
NCT01221753
Terminated
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer. An approved treatment for squamous cell carcinoma of the head and neck is initial chemotherapy followed by radiation and chemotherapy together. This treatment is effective but has many immediate and long-term side effects. People who have squamous cell carcinoma of the head and neck (SSCHN) th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2017
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Register for Updates
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00526890
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with selenomethionine and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well sele... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Lung Cancer
Register for Updates